nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—psoriatic arthritis—psoriasis	0.426	0.574	CtDrD
Auranofin—rheumatoid arthritis—psoriasis	0.316	0.426	CtDrD
Auranofin—ALB—Acitretin—psoriasis	0.0608	0.492	CbGbCtD
Auranofin—ALB—Mycophenolate mofetil—psoriasis	0.0284	0.231	CbGbCtD
Auranofin—ALB—Prednisone—psoriasis	0.0227	0.184	CbGbCtD
Auranofin—ALB—Methotrexate—psoriasis	0.0114	0.0925	CbGbCtD
Auranofin—Dysphagia—Cyclosporine—psoriasis	0.000211	0.00329	CcSEcCtD
Auranofin—Protein urine present—Methotrexate—psoriasis	0.000209	0.00326	CcSEcCtD
Auranofin—Gastrointestinal pain—Calcitriol—psoriasis	0.000207	0.00324	CcSEcCtD
Auranofin—Dysphagia—Mycophenolate mofetil—psoriasis	0.000206	0.00321	CcSEcCtD
Auranofin—Glossitis—Methotrexate—psoriasis	0.000202	0.00315	CcSEcCtD
Auranofin—Urticaria—Calcitriol—psoriasis	0.000202	0.00314	CcSEcCtD
Auranofin—Pruritus—Methoxsalen—psoriasis	0.000201	0.00314	CcSEcCtD
Auranofin—Visual impairment—Mycophenolic acid—psoriasis	0.000201	0.00314	CcSEcCtD
Auranofin—Anaemia—Hydroxyurea—psoriasis	0.000201	0.00313	CcSEcCtD
Auranofin—Abdominal pain—Calcitriol—psoriasis	0.000201	0.00313	CcSEcCtD
Auranofin—Dyspepsia—Acitretin—psoriasis	0.000199	0.0031	CcSEcCtD
Auranofin—Hepatic enzyme increased—Methotrexate—psoriasis	0.000197	0.00307	CcSEcCtD
Auranofin—Decreased appetite—Acitretin—psoriasis	0.000196	0.00306	CcSEcCtD
Auranofin—Pancytopenia—Mycophenolate mofetil—psoriasis	0.000196	0.00305	CcSEcCtD
Auranofin—Eye disorder—Mycophenolic acid—psoriasis	0.000195	0.00305	CcSEcCtD
Auranofin—Leukopenia—Hydroxyurea—psoriasis	0.000194	0.00303	CcSEcCtD
Auranofin—Constipation—Acitretin—psoriasis	0.000193	0.00301	CcSEcCtD
Auranofin—Neutropenia—Mycophenolate mofetil—psoriasis	0.000193	0.003	CcSEcCtD
Auranofin—Weight decreased—Cyclosporine—psoriasis	0.000191	0.00298	CcSEcCtD
Auranofin—Weight decreased—Mycophenolate mofetil—psoriasis	0.000186	0.00291	CcSEcCtD
Auranofin—Alopecia—Mycophenolic acid—psoriasis	0.000185	0.00288	CcSEcCtD
Auranofin—Gastrointestinal pain—Acitretin—psoriasis	0.000185	0.00288	CcSEcCtD
Auranofin—Neuropathy peripheral—Cyclosporine—psoriasis	0.000185	0.00288	CcSEcCtD
Auranofin—Stomatitis—Cyclosporine—psoriasis	0.000184	0.00286	CcSEcCtD
Auranofin—Jaundice—Cyclosporine—psoriasis	0.000184	0.00286	CcSEcCtD
Auranofin—Conjunctivitis—Cyclosporine—psoriasis	0.000183	0.00285	CcSEcCtD
Auranofin—Melaena—Methotrexate—psoriasis	0.000182	0.00283	CcSEcCtD
Auranofin—Neuropathy peripheral—Mycophenolate mofetil—psoriasis	0.00018	0.00281	CcSEcCtD
Auranofin—Pruritus—Calcitriol—psoriasis	0.00018	0.0028	CcSEcCtD
Auranofin—Haematuria—Cyclosporine—psoriasis	0.00018	0.0028	CcSEcCtD
Auranofin—Rash—Methoxsalen—psoriasis	0.000179	0.0028	CcSEcCtD
Auranofin—Dermatitis—Methoxsalen—psoriasis	0.000179	0.0028	CcSEcCtD
Auranofin—Urticaria—Acitretin—psoriasis	0.000179	0.0028	CcSEcCtD
Auranofin—Flatulence—Mycophenolic acid—psoriasis	0.000179	0.0028	CcSEcCtD
Auranofin—Jaundice—Mycophenolate mofetil—psoriasis	0.000179	0.00279	CcSEcCtD
Auranofin—Stomatitis—Mycophenolate mofetil—psoriasis	0.000179	0.00279	CcSEcCtD
Auranofin—Conjunctivitis—Mycophenolate mofetil—psoriasis	0.000179	0.00278	CcSEcCtD
Auranofin—Abdominal pain—Acitretin—psoriasis	0.000178	0.00278	CcSEcCtD
Auranofin—Haematuria—Mycophenolate mofetil—psoriasis	0.000175	0.00273	CcSEcCtD
Auranofin—Aplastic anaemia—Methotrexate—psoriasis	0.000175	0.00272	CcSEcCtD
Auranofin—Diarrhoea—Calcitriol—psoriasis	0.000174	0.00271	CcSEcCtD
Auranofin—Thrombocytopenia—Hydroxyurea—psoriasis	0.000174	0.00271	CcSEcCtD
Auranofin—Agranulocytosis—Mycophenolate mofetil—psoriasis	0.000171	0.00267	CcSEcCtD
Auranofin—Weight decreased—Hydrocortisone—psoriasis	0.00017	0.00265	CcSEcCtD
Auranofin—Nausea—Methoxsalen—psoriasis	0.000169	0.00264	CcSEcCtD
Auranofin—Anorexia—Hydroxyurea—psoriasis	0.000169	0.00263	CcSEcCtD
Auranofin—Anaemia—Mycophenolic acid—psoriasis	0.000168	0.00262	CcSEcCtD
Auranofin—Neuropathy peripheral—Prednisolone—psoriasis	0.000168	0.00262	CcSEcCtD
Auranofin—Conjunctivitis—Prednisolone—psoriasis	0.000167	0.0026	CcSEcCtD
Auranofin—Neuropathy peripheral—Hydrocortisone—psoriasis	0.000164	0.00256	CcSEcCtD
Auranofin—Visual impairment—Cyclosporine—psoriasis	0.000163	0.00254	CcSEcCtD
Auranofin—Leukopenia—Mycophenolic acid—psoriasis	0.000163	0.00254	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Prednisone—psoriasis	0.000162	0.00252	CcSEcCtD
Auranofin—Vomiting—Calcitriol—psoriasis	0.000161	0.00252	CcSEcCtD
Auranofin—Rash—Calcitriol—psoriasis	0.00016	0.0025	CcSEcCtD
Auranofin—Dermatitis—Calcitriol—psoriasis	0.00016	0.00249	CcSEcCtD
Auranofin—Pruritus—Acitretin—psoriasis	0.00016	0.00249	CcSEcCtD
Auranofin—Pruritus—Fluocinolone Acetonide—psoriasis	0.000159	0.00248	CcSEcCtD
Auranofin—Visual impairment—Mycophenolate mofetil—psoriasis	0.000159	0.00248	CcSEcCtD
Auranofin—Dyspepsia—Hydroxyurea—psoriasis	0.000156	0.00243	CcSEcCtD
Auranofin—Diarrhoea—Acitretin—psoriasis	0.000154	0.00241	CcSEcCtD
Auranofin—Neuropathy peripheral—Triamcinolone—psoriasis	0.000154	0.00241	CcSEcCtD
Auranofin—Eye disorder—Mycophenolate mofetil—psoriasis	0.000154	0.0024	CcSEcCtD
Auranofin—Decreased appetite—Hydroxyurea—psoriasis	0.000154	0.0024	CcSEcCtD
Auranofin—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000154	0.0024	CcSEcCtD
Auranofin—Conjunctivitis—Triamcinolone—psoriasis	0.000153	0.00239	CcSEcCtD
Auranofin—Constipation—Hydroxyurea—psoriasis	0.000152	0.00236	CcSEcCtD
Auranofin—Nausea—Calcitriol—psoriasis	0.000151	0.00235	CcSEcCtD
Auranofin—Alopecia—Cyclosporine—psoriasis	0.000149	0.00233	CcSEcCtD
Auranofin—Visual impairment—Prednisolone—psoriasis	0.000148	0.00231	CcSEcCtD
Auranofin—Alopecia—Mycophenolate mofetil—psoriasis	0.000146	0.00227	CcSEcCtD
Auranofin—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000145	0.00227	CcSEcCtD
Auranofin—Weight decreased—Dexamethasone—psoriasis	0.000145	0.00226	CcSEcCtD
Auranofin—Weight decreased—Betamethasone—psoriasis	0.000145	0.00226	CcSEcCtD
Auranofin—Flatulence—Cyclosporine—psoriasis	0.000145	0.00226	CcSEcCtD
Auranofin—Dysgeusia—Cyclosporine—psoriasis	0.000144	0.00225	CcSEcCtD
Auranofin—Vomiting—Acitretin—psoriasis	0.000144	0.00224	CcSEcCtD
Auranofin—Vomiting—Fluocinolone Acetonide—psoriasis	0.000143	0.00223	CcSEcCtD
Auranofin—Dermatitis exfoliative—Methotrexate—psoriasis	0.000143	0.00223	CcSEcCtD
Auranofin—Rash—Acitretin—psoriasis	0.000142	0.00222	CcSEcCtD
Auranofin—Dermatitis—Acitretin—psoriasis	0.000142	0.00222	CcSEcCtD
Auranofin—Rash—Fluocinolone Acetonide—psoriasis	0.000142	0.00221	CcSEcCtD
Auranofin—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000142	0.00221	CcSEcCtD
Auranofin—Anorexia—Mycophenolic acid—psoriasis	0.000141	0.00221	CcSEcCtD
Auranofin—Flatulence—Mycophenolate mofetil—psoriasis	0.000141	0.00221	CcSEcCtD
Auranofin—Dysgeusia—Mycophenolate mofetil—psoriasis	0.000141	0.00219	CcSEcCtD
Auranofin—Eye disorder—Hydrocortisone—psoriasis	0.00014	0.00219	CcSEcCtD
Auranofin—Neuropathy peripheral—Betamethasone—psoriasis	0.00014	0.00219	CcSEcCtD
Auranofin—Neuropathy peripheral—Dexamethasone—psoriasis	0.00014	0.00219	CcSEcCtD
Auranofin—Conjunctivitis—Dexamethasone—psoriasis	0.000139	0.00217	CcSEcCtD
Auranofin—Conjunctivitis—Betamethasone—psoriasis	0.000139	0.00217	CcSEcCtD
Auranofin—Anaemia—Cyclosporine—psoriasis	0.000136	0.00212	CcSEcCtD
Auranofin—Angioedema—Cyclosporine—psoriasis	0.000134	0.0021	CcSEcCtD
Auranofin—Nausea—Acitretin—psoriasis	0.000134	0.00209	CcSEcCtD
Auranofin—Nausea—Fluocinolone Acetonide—psoriasis	0.000134	0.00209	CcSEcCtD
Auranofin—Anaemia—Mycophenolate mofetil—psoriasis	0.000133	0.00207	CcSEcCtD
Auranofin—Leukopenia—Cyclosporine—psoriasis	0.000132	0.00205	CcSEcCtD
Auranofin—Angioedema—Mycophenolate mofetil—psoriasis	0.000131	0.00205	CcSEcCtD
Auranofin—Dyspepsia—Mycophenolic acid—psoriasis	0.000131	0.00204	CcSEcCtD
Auranofin—Neutropenia—Prednisone—psoriasis	0.000131	0.00204	CcSEcCtD
Auranofin—Decreased appetite—Mycophenolic acid—psoriasis	0.000129	0.00201	CcSEcCtD
Auranofin—Leukopenia—Mycophenolate mofetil—psoriasis	0.000128	0.002	CcSEcCtD
Auranofin—Constipation—Mycophenolic acid—psoriasis	0.000127	0.00198	CcSEcCtD
Auranofin—Weight decreased—Prednisone—psoriasis	0.000126	0.00197	CcSEcCtD
Auranofin—Visual impairment—Dexamethasone—psoriasis	0.000124	0.00193	CcSEcCtD
Auranofin—Visual impairment—Betamethasone—psoriasis	0.000124	0.00193	CcSEcCtD
Auranofin—Angioedema—Prednisolone—psoriasis	0.000122	0.00191	CcSEcCtD
Auranofin—Neuropathy peripheral—Prednisone—psoriasis	0.000122	0.0019	CcSEcCtD
Auranofin—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000121	0.00189	CcSEcCtD
Auranofin—Diarrhoea—Hydroxyurea—psoriasis	0.000121	0.00189	CcSEcCtD
Auranofin—Dysgeusia—Triamcinolone—psoriasis	0.000121	0.00188	CcSEcCtD
Auranofin—Eye disorder—Dexamethasone—psoriasis	0.00012	0.00187	CcSEcCtD
Auranofin—Eye disorder—Betamethasone—psoriasis	0.00012	0.00187	CcSEcCtD
Auranofin—Angioedema—Hydrocortisone—psoriasis	0.000119	0.00186	CcSEcCtD
Auranofin—Thrombocytopenia—Cyclosporine—psoriasis	0.000118	0.00183	CcSEcCtD
Auranofin—Abdominal pain—Mycophenolic acid—psoriasis	0.000117	0.00183	CcSEcCtD
Auranofin—IKBKB—Cardiac Hypertrophic Response—NFKB1—psoriasis	0.000117	0.00166	CbGpPWpGaD
Auranofin—IKBKB—B Cell Receptor Signaling Pathway—NFKBIA—psoriasis	0.000116	0.00165	CbGpPWpGaD
Auranofin—IKBKB—Immune System—KIR2DS1—psoriasis	0.000116	0.00165	CbGpPWpGaD
Auranofin—Eosinophilia—Methotrexate—psoriasis	0.000116	0.0018	CcSEcCtD
Auranofin—ALB—Folate Metabolism—CAT—psoriasis	0.000115	0.00164	CbGpPWpGaD
Auranofin—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000115	0.00179	CcSEcCtD
Auranofin—Anorexia—Cyclosporine—psoriasis	0.000114	0.00179	CcSEcCtD
Auranofin—IKBKB—MyD88-independent cascade—NFKBIA—psoriasis	0.000114	0.00163	CbGpPWpGaD
Auranofin—Alopecia—Betamethasone—psoriasis	0.000113	0.00177	CcSEcCtD
Auranofin—Alopecia—Dexamethasone—psoriasis	0.000113	0.00177	CcSEcCtD
Auranofin—IKBKB—Insulin Signaling—SOCS1—psoriasis	0.000113	0.00161	CbGpPWpGaD
Auranofin—Vomiting—Hydroxyurea—psoriasis	0.000113	0.00176	CcSEcCtD
Auranofin—Angioedema—Triamcinolone—psoriasis	0.000112	0.00175	CcSEcCtD
Auranofin—IKBKB—TWEAK Signaling Pathway—TNF—psoriasis	0.000112	0.0016	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—CRP—psoriasis	0.000112	0.0016	CbGpPWpGaD
Auranofin—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	0.000112	0.00159	CbGpPWpGaD
Auranofin—Rash—Hydroxyurea—psoriasis	0.000112	0.00174	CcSEcCtD
Auranofin—Anorexia—Mycophenolate mofetil—psoriasis	0.000112	0.00174	CcSEcCtD
Auranofin—Dermatitis—Hydroxyurea—psoriasis	0.000112	0.00174	CcSEcCtD
Auranofin—IKBKB—Fc-epsilon receptor I signaling in mast cells—JUN—psoriasis	0.000111	0.00159	CbGpPWpGaD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—NFKBIA—psoriasis	0.000111	0.00159	CbGpPWpGaD
Auranofin—Pancytopenia—Methotrexate—psoriasis	0.000111	0.00173	CcSEcCtD
Auranofin—IKBKB—TCR signaling—NFKB1—psoriasis	0.00011	0.00157	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—APOE—psoriasis	0.00011	0.00157	CbGpPWpGaD
Auranofin—Neutropenia—Methotrexate—psoriasis	0.000109	0.0017	CcSEcCtD
Auranofin—IKBKB—Fc-epsilon receptor I signaling in mast cells—NFKB1—psoriasis	0.000107	0.00153	CbGpPWpGaD
Auranofin—IKBKB—IL-4 Signaling Pathway—STAT3—psoriasis	0.000106	0.00152	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—IL4—psoriasis	0.000106	0.00151	CbGpPWpGaD
Auranofin—Dyspepsia—Cyclosporine—psoriasis	0.000106	0.00165	CcSEcCtD
Auranofin—IKBKB—MyD88 cascade initiated on plasma membrane—TYK2—psoriasis	0.000106	0.00151	CbGpPWpGaD
Auranofin—Nausea—Hydroxyurea—psoriasis	0.000105	0.00164	CcSEcCtD
Auranofin—Pruritus—Mycophenolic acid—psoriasis	0.000105	0.00164	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—JUN—psoriasis	0.000105	0.00149	CbGpPWpGaD
Auranofin—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—TYK2—psoriasis	0.000105	0.00149	CbGpPWpGaD
Auranofin—IKBKB—TNF receptor signaling pathway —TNF—psoriasis	0.000105	0.00149	CbGpPWpGaD
Auranofin—Eye disorder—Prednisone—psoriasis	0.000104	0.00163	CcSEcCtD
Auranofin—Decreased appetite—Cyclosporine—psoriasis	0.000104	0.00163	CcSEcCtD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-C—psoriasis	0.000104	0.00149	CbGpPWpGaD
Auranofin—IKBKB—BCR signaling pathway—JUN—psoriasis	0.000103	0.00147	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000103	0.00147	CbGpPWpGaD
Auranofin—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000103	0.00161	CcSEcCtD
Auranofin—Constipation—Cyclosporine—psoriasis	0.000103	0.0016	CcSEcCtD
Auranofin—IKBKB—MyD88 dependent cascade initiated on endosome—TYK2—psoriasis	0.000103	0.00146	CbGpPWpGaD
Auranofin—IKBKB—Activated TLR4 signalling—NFKBIA—psoriasis	0.000103	0.00146	CbGpPWpGaD
Auranofin—Angioedema—Dexamethasone—psoriasis	0.000102	0.00159	CcSEcCtD
Auranofin—Angioedema—Betamethasone—psoriasis	0.000102	0.00159	CcSEcCtD
Auranofin—IKBKB—Activation of NF-kappaB in B cells—NFKB1—psoriasis	0.000102	0.00145	CbGpPWpGaD
Auranofin—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000102	0.00159	CcSEcCtD
Auranofin—Anorexia—Hydrocortisone—psoriasis	0.000102	0.00159	CcSEcCtD
Auranofin—Diarrhoea—Mycophenolic acid—psoriasis	0.000102	0.00158	CcSEcCtD
Auranofin—Stomatitis—Methotrexate—psoriasis	0.000101	0.00158	CcSEcCtD
Auranofin—Conjunctivitis—Methotrexate—psoriasis	0.000101	0.00158	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—NFKB1—psoriasis	0.000101	0.00144	CbGpPWpGaD
Auranofin—IKBKB—Cytosolic sensors of pathogen-associated DNA—NFKB1—psoriasis	0.000101	0.00144	CbGpPWpGaD
Auranofin—Constipation—Mycophenolate mofetil—psoriasis	0.0001	0.00156	CcSEcCtD
Auranofin—IKBKB—BCR signaling pathway—NFKB1—psoriasis	9.95e-05	0.00142	CbGpPWpGaD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—NFKB1—psoriasis	9.95e-05	0.00142	CbGpPWpGaD
Auranofin—Haematuria—Methotrexate—psoriasis	9.92e-05	0.00155	CcSEcCtD
Auranofin—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—TYK2—psoriasis	9.91e-05	0.00141	CbGpPWpGaD
Auranofin—Alopecia—Prednisone—psoriasis	9.88e-05	0.00154	CcSEcCtD
Auranofin—Gastrointestinal pain—Cyclosporine—psoriasis	9.82e-05	0.00153	CcSEcCtD
Auranofin—IKBKB—Adaptive Immune System—ERAP1—psoriasis	9.77e-05	0.00139	CbGpPWpGaD
Auranofin—IKBKB—MyD88:Mal cascade initiated on plasma membrane—TYK2—psoriasis	9.74e-05	0.00139	CbGpPWpGaD
Auranofin—Agranulocytosis—Methotrexate—psoriasis	9.71e-05	0.00151	CcSEcCtD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—NFKBIA—psoriasis	9.65e-05	0.00138	CbGpPWpGaD
Auranofin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	9.58e-05	0.00149	CcSEcCtD
Auranofin—Urticaria—Cyclosporine—psoriasis	9.54e-05	0.00149	CcSEcCtD
Auranofin—Abdominal pain—Cyclosporine—psoriasis	9.49e-05	0.00148	CcSEcCtD
Auranofin—IKBKB—TRAF6 Mediated Induction of proinflammatory cytokines—JUN—psoriasis	9.44e-05	0.00135	CbGpPWpGaD
Auranofin—Vomiting—Mycophenolic acid—psoriasis	9.44e-05	0.00147	CcSEcCtD
Auranofin—Dyspepsia—Hydrocortisone—psoriasis	9.39e-05	0.00147	CcSEcCtD
Auranofin—Rash—Mycophenolic acid—psoriasis	9.36e-05	0.00146	CcSEcCtD
Auranofin—Dermatitis—Mycophenolic acid—psoriasis	9.35e-05	0.00146	CcSEcCtD
Auranofin—IKBKB—MyD88-independent cascade—TYK2—psoriasis	9.34e-05	0.00133	CbGpPWpGaD
Auranofin—Urticaria—Mycophenolate mofetil—psoriasis	9.31e-05	0.00145	CcSEcCtD
Auranofin—Decreased appetite—Hydrocortisone—psoriasis	9.28e-05	0.00145	CcSEcCtD
Auranofin—Abdominal pain—Mycophenolate mofetil—psoriasis	9.26e-05	0.00144	CcSEcCtD
Auranofin—ALB—Selenium Micronutrient Network—CAT—psoriasis	9.15e-05	0.00131	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—CRP—psoriasis	9.14e-05	0.0013	CbGpPWpGaD
Auranofin—IKBKB—TCR Signaling Pathway—CD4—psoriasis	9.12e-05	0.0013	CbGpPWpGaD
Auranofin—IKBKB—TRAF6 Mediated Induction of proinflammatory cytokines—NFKB1—psoriasis	9.09e-05	0.0013	CbGpPWpGaD
Auranofin—IKBKB—Leptin signaling pathway—NFKB1—psoriasis	9.09e-05	0.0013	CbGpPWpGaD
Auranofin—IKBKB—TWEAK Signaling Pathway—IL6—psoriasis	9.07e-05	0.00129	CbGpPWpGaD
Auranofin—IKBKB—Cardiac Hypertrophic Response—TNF—psoriasis	9.06e-05	0.00129	CbGpPWpGaD
Auranofin—IKBKB—AGE/RAGE pathway—STAT3—psoriasis	9.05e-05	0.00129	CbGpPWpGaD
Auranofin—Visual impairment—Methotrexate—psoriasis	9e-05	0.0014	CcSEcCtD
Auranofin—Anaemia—Prednisone—psoriasis	8.99e-05	0.0014	CcSEcCtD
Auranofin—IKBKB—Innate Immune System—DDX58—psoriasis	8.95e-05	0.00128	CbGpPWpGaD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—STAT3—psoriasis	8.94e-05	0.00128	CbGpPWpGaD
Auranofin—Thrombocytopenia—Betamethasone—psoriasis	8.93e-05	0.00139	CcSEcCtD
Auranofin—Thrombocytopenia—Dexamethasone—psoriasis	8.93e-05	0.00139	CcSEcCtD
Auranofin—Angioedema—Prednisone—psoriasis	8.89e-05	0.00139	CcSEcCtD
Auranofin—Dyspepsia—Triamcinolone—psoriasis	8.84e-05	0.00138	CcSEcCtD
Auranofin—Nausea—Mycophenolic acid—psoriasis	8.82e-05	0.00138	CcSEcCtD
Auranofin—Eye disorder—Methotrexate—psoriasis	8.73e-05	0.00136	CcSEcCtD
Auranofin—Gastrointestinal pain—Hydrocortisone—psoriasis	8.73e-05	0.00136	CcSEcCtD
Auranofin—IKBKB—Signaling by Interleukins—TYK2—psoriasis	8.72e-05	0.00124	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—NFKBIA—psoriasis	8.7e-05	0.00124	CbGpPWpGaD
Auranofin—Anorexia—Betamethasone—psoriasis	8.69e-05	0.00136	CcSEcCtD
Auranofin—Anorexia—Dexamethasone—psoriasis	8.69e-05	0.00136	CcSEcCtD
Auranofin—Urticaria—Prednisolone—psoriasis	8.68e-05	0.00135	CcSEcCtD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-E—psoriasis	8.65e-05	0.00123	CbGpPWpGaD
Auranofin—IKBKB—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—NFKB1—psoriasis	8.63e-05	0.00123	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—JUN—psoriasis	8.63e-05	0.00123	CbGpPWpGaD
Auranofin—IKBKB—Toll-Like Receptors Cascades—NFKBIA—psoriasis	8.6e-05	0.00123	CbGpPWpGaD
Auranofin—IKBKB—MyD88 cascade initiated on plasma membrane—JUN—psoriasis	8.54e-05	0.00122	CbGpPWpGaD
Auranofin—Pruritus—Cyclosporine—psoriasis	8.5e-05	0.00132	CcSEcCtD
Auranofin—Urticaria—Hydrocortisone—psoriasis	8.48e-05	0.00132	CcSEcCtD
Auranofin—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—psoriasis	8.46e-05	0.00121	CbGpPWpGaD
Auranofin—IKBKB—p75 NTR receptor-mediated signalling—NFKB1—psoriasis	8.46e-05	0.00121	CbGpPWpGaD
Auranofin—IKBKB—BDNF signaling pathway—NFKBIA—psoriasis	8.45e-05	0.00121	CbGpPWpGaD
Auranofin—Abdominal pain—Hydrocortisone—psoriasis	8.44e-05	0.00132	CcSEcCtD
Auranofin—ALB—Folate Metabolism—ICAM1—psoriasis	8.41e-05	0.0012	CbGpPWpGaD
Auranofin—IKBKB—Activated TLR4 signalling—TYK2—psoriasis	8.41e-05	0.0012	CbGpPWpGaD
Auranofin—IKBKB—MyD88 dependent cascade initiated on endosome—JUN—psoriasis	8.31e-05	0.00119	CbGpPWpGaD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—psoriasis	8.3e-05	0.00118	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—NFKB1—psoriasis	8.3e-05	0.00118	CbGpPWpGaD
Auranofin—Pruritus—Mycophenolate mofetil—psoriasis	8.29e-05	0.00129	CcSEcCtD
Auranofin—Alopecia—Methotrexate—psoriasis	8.25e-05	0.00129	CcSEcCtD
Auranofin—IKBKB—MyD88 cascade initiated on plasma membrane—NFKB1—psoriasis	8.22e-05	0.00117	CbGpPWpGaD
Auranofin—Diarrhoea—Cyclosporine—psoriasis	8.22e-05	0.00128	CcSEcCtD
Auranofin—IKBKB—Leptin signaling pathway—STAT3—psoriasis	8.17e-05	0.00117	CbGpPWpGaD
Auranofin—IKBKB—TCR Signaling Pathway—JUN—psoriasis	8.16e-05	0.00116	CbGpPWpGaD
Auranofin—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKB1—psoriasis	8.15e-05	0.00116	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—JUN—psoriasis	8.09e-05	0.00115	CbGpPWpGaD
Auranofin—Dyspepsia—Betamethasone—psoriasis	8.03e-05	0.00125	CcSEcCtD
Auranofin—Dyspepsia—Dexamethasone—psoriasis	8.03e-05	0.00125	CcSEcCtD
Auranofin—IKBKB—TNF alpha Signaling Pathway—JUN—psoriasis	8.02e-05	0.00114	CbGpPWpGaD
Auranofin—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—JUN—psoriasis	8.02e-05	0.00114	CbGpPWpGaD
Auranofin—Diarrhoea—Mycophenolate mofetil—psoriasis	8.01e-05	0.00125	CcSEcCtD
Auranofin—IKBKB—MyD88 dependent cascade initiated on endosome—NFKB1—psoriasis	8e-05	0.00114	CbGpPWpGaD
Auranofin—Urticaria—Triamcinolone—psoriasis	7.98e-05	0.00125	CcSEcCtD
Auranofin—Dysgeusia—Methotrexate—psoriasis	7.96e-05	0.00124	CcSEcCtD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—CXCL8—psoriasis	7.94e-05	0.00113	CbGpPWpGaD
Auranofin—Decreased appetite—Dexamethasone—psoriasis	7.93e-05	0.00124	CcSEcCtD
Auranofin—Decreased appetite—Betamethasone—psoriasis	7.93e-05	0.00124	CcSEcCtD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—TYK2—psoriasis	7.91e-05	0.00113	CbGpPWpGaD
Auranofin—IKBKB—MyD88:Mal cascade initiated on plasma membrane—JUN—psoriasis	7.88e-05	0.00112	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	7.86e-05	0.00112	CbGpPWpGaD
Auranofin—IKBKB—TCR Signaling Pathway—NFKB1—psoriasis	7.86e-05	0.00112	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—NFKB1—psoriasis	7.79e-05	0.00111	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—NFKB1—psoriasis	7.72e-05	0.0011	CbGpPWpGaD
Auranofin—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—NFKB1—psoriasis	7.72e-05	0.0011	CbGpPWpGaD
Auranofin—IKBKB—B Cell Receptor Signaling Pathway—JUN—psoriasis	7.69e-05	0.0011	CbGpPWpGaD
Auranofin—Vomiting—Cyclosporine—psoriasis	7.63e-05	0.00119	CcSEcCtD
Auranofin—IKBKB—MyD88:Mal cascade initiated on plasma membrane—NFKB1—psoriasis	7.59e-05	0.00108	CbGpPWpGaD
Auranofin—Rash—Cyclosporine—psoriasis	7.57e-05	0.00118	CcSEcCtD
Auranofin—Anorexia—Prednisone—psoriasis	7.57e-05	0.00118	CcSEcCtD
Auranofin—Dermatitis—Cyclosporine—psoriasis	7.56e-05	0.00118	CcSEcCtD
Auranofin—IKBKB—MyD88-independent cascade—JUN—psoriasis	7.56e-05	0.00108	CbGpPWpGaD
Auranofin—Pruritus—Hydrocortisone—psoriasis	7.55e-05	0.00118	CcSEcCtD
Auranofin—Anaemia—Methotrexate—psoriasis	7.51e-05	0.00117	CcSEcCtD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—psoriasis	7.51e-05	0.00107	CbGpPWpGaD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	7.46e-05	0.00106	CbGpPWpGaD
Auranofin—Gastrointestinal pain—Betamethasone—psoriasis	7.46e-05	0.00116	CcSEcCtD
Auranofin—Gastrointestinal pain—Dexamethasone—psoriasis	7.46e-05	0.00116	CcSEcCtD
Auranofin—Vomiting—Mycophenolate mofetil—psoriasis	7.45e-05	0.00116	CcSEcCtD
Auranofin—IKBKB—B Cell Receptor Signaling Pathway—NFKB1—psoriasis	7.4e-05	0.00106	CbGpPWpGaD
Auranofin—Rash—Mycophenolate mofetil—psoriasis	7.39e-05	0.00115	CcSEcCtD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—JUN—psoriasis	7.38e-05	0.00105	CbGpPWpGaD
Auranofin—Dermatitis—Mycophenolate mofetil—psoriasis	7.38e-05	0.00115	CcSEcCtD
Auranofin—Diarrhoea—Hydrocortisone—psoriasis	7.3e-05	0.00114	CcSEcCtD
Auranofin—IKBKB—MyD88-independent cascade—NFKB1—psoriasis	7.28e-05	0.00104	CbGpPWpGaD
Auranofin—Leukopenia—Methotrexate—psoriasis	7.28e-05	0.00114	CcSEcCtD
Auranofin—ALB—Selenium Micronutrient Network—CRP—psoriasis	7.26e-05	0.00104	CbGpPWpGaD
Auranofin—Urticaria—Dexamethasone—psoriasis	7.24e-05	0.00113	CcSEcCtD
Auranofin—Urticaria—Betamethasone—psoriasis	7.24e-05	0.00113	CcSEcCtD
Auranofin—IKBKB—Cytokine Signaling in Immune system—SOCS1—psoriasis	7.22e-05	0.00103	CbGpPWpGaD
Auranofin—Abdominal pain—Dexamethasone—psoriasis	7.21e-05	0.00112	CcSEcCtD
Auranofin—Abdominal pain—Betamethasone—psoriasis	7.21e-05	0.00112	CcSEcCtD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—NFKBIA—psoriasis	7.17e-05	0.00102	CbGpPWpGaD
Auranofin—Nausea—Cyclosporine—psoriasis	7.13e-05	0.00111	CcSEcCtD
Auranofin—Pruritus—Triamcinolone—psoriasis	7.11e-05	0.00111	CcSEcCtD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	7.11e-05	0.00101	CbGpPWpGaD
Auranofin—IKBKB—Toll-Like Receptors Cascades—TYK2—psoriasis	7.04e-05	0.001	CbGpPWpGaD
Auranofin—Dyspepsia—Prednisone—psoriasis	6.99e-05	0.00109	CcSEcCtD
Auranofin—Nausea—Mycophenolate mofetil—psoriasis	6.96e-05	0.00109	CcSEcCtD
Auranofin—Decreased appetite—Prednisone—psoriasis	6.9e-05	0.00108	CcSEcCtD
Auranofin—Rash—Prednisolone—psoriasis	6.89e-05	0.00107	CcSEcCtD
Auranofin—Dermatitis—Prednisolone—psoriasis	6.88e-05	0.00107	CcSEcCtD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—TP53—psoriasis	6.82e-05	0.000973	CbGpPWpGaD
Auranofin—IKBKB—Activated TLR4 signalling—JUN—psoriasis	6.8e-05	0.00097	CbGpPWpGaD
Auranofin—IKBKB—Signaling by Interleukins—NFKB1—psoriasis	6.79e-05	0.000969	CbGpPWpGaD
Auranofin—Constipation—Prednisone—psoriasis	6.79e-05	0.00106	CcSEcCtD
Auranofin—Vomiting—Hydrocortisone—psoriasis	6.78e-05	0.00106	CcSEcCtD
Auranofin—Rash—Hydrocortisone—psoriasis	6.73e-05	0.00105	CcSEcCtD
Auranofin—Dermatitis—Hydrocortisone—psoriasis	6.72e-05	0.00105	CcSEcCtD
Auranofin—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	6.68e-05	0.000952	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—TP53—psoriasis	6.66e-05	0.000951	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—NFKBIA—psoriasis	6.63e-05	0.000946	CbGpPWpGaD
Auranofin—ALB—SLC-mediated transmembrane transport—CP—psoriasis	6.55e-05	0.000935	CbGpPWpGaD
Auranofin—IKBKB—Activated TLR4 signalling—NFKB1—psoriasis	6.55e-05	0.000934	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	6.54e-05	0.000933	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—ITGAL—psoriasis	6.52e-05	0.00093	CbGpPWpGaD
Auranofin—Thrombocytopenia—Methotrexate—psoriasis	6.5e-05	0.00101	CcSEcCtD
Auranofin—Gastrointestinal pain—Prednisone—psoriasis	6.49e-05	0.00101	CcSEcCtD
Auranofin—Nausea—Prednisolone—psoriasis	6.49e-05	0.00101	CcSEcCtD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriasis	6.46e-05	0.000921	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—TNF—psoriasis	6.46e-05	0.000921	CbGpPWpGaD
Auranofin—Pruritus—Betamethasone—psoriasis	6.45e-05	0.00101	CcSEcCtD
Auranofin—Pruritus—Dexamethasone—psoriasis	6.45e-05	0.00101	CcSEcCtD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—JUN—psoriasis	6.4e-05	0.000913	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—IFNG—psoriasis	6.4e-05	0.000912	CbGpPWpGaD
Auranofin—Vomiting—Triamcinolone—psoriasis	6.39e-05	0.000996	CcSEcCtD
Auranofin—Nausea—Hydrocortisone—psoriasis	6.34e-05	0.000989	CcSEcCtD
Auranofin—Rash—Triamcinolone—psoriasis	6.34e-05	0.000988	CcSEcCtD
Auranofin—Dermatitis—Triamcinolone—psoriasis	6.33e-05	0.000987	CcSEcCtD
Auranofin—Anorexia—Methotrexate—psoriasis	6.33e-05	0.000987	CcSEcCtD
Auranofin—Urticaria—Prednisone—psoriasis	6.31e-05	0.000984	CcSEcCtD
Auranofin—Abdominal pain—Prednisone—psoriasis	6.28e-05	0.000979	CcSEcCtD
Auranofin—Diarrhoea—Betamethasone—psoriasis	6.24e-05	0.000973	CcSEcCtD
Auranofin—Diarrhoea—Dexamethasone—psoriasis	6.24e-05	0.000973	CcSEcCtD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	6.2e-05	0.000885	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—IFIH1—psoriasis	6.16e-05	0.000879	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-B—psoriasis	6.16e-05	0.000879	CbGpPWpGaD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—NFKB1—psoriasis	6.16e-05	0.000879	CbGpPWpGaD
Auranofin—IKBKB—Signaling by Interleukins—STAT3—psoriasis	6.1e-05	0.00087	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—REL—psoriasis	6.1e-05	0.000869	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—TNF—psoriasis	6e-05	0.000857	CbGpPWpGaD
Auranofin—Nausea—Triamcinolone—psoriasis	5.97e-05	0.000931	CcSEcCtD
Auranofin—IKBKB—Immune System—ERAP1—psoriasis	5.92e-05	0.000845	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	5.87e-05	0.000837	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—HLA-C—psoriasis	5.84e-05	0.000833	CbGpPWpGaD
Auranofin—Dyspepsia—Methotrexate—psoriasis	5.84e-05	0.000911	CcSEcCtD
Auranofin—Vomiting—Betamethasone—psoriasis	5.8e-05	0.000904	CcSEcCtD
Auranofin—Vomiting—Dexamethasone—psoriasis	5.8e-05	0.000904	CcSEcCtD
Auranofin—IKBKB—Innate Immune System—TNFAIP3—psoriasis	5.77e-05	0.000823	CbGpPWpGaD
Auranofin—Decreased appetite—Methotrexate—psoriasis	5.77e-05	0.0009	CcSEcCtD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	5.76e-05	0.000822	CbGpPWpGaD
Auranofin—Rash—Dexamethasone—psoriasis	5.75e-05	0.000897	CcSEcCtD
Auranofin—Rash—Betamethasone—psoriasis	5.75e-05	0.000897	CcSEcCtD
Auranofin—Dermatitis—Dexamethasone—psoriasis	5.74e-05	0.000896	CcSEcCtD
Auranofin—Dermatitis—Betamethasone—psoriasis	5.74e-05	0.000896	CcSEcCtD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-A—psoriasis	5.71e-05	0.000814	CbGpPWpGaD
Auranofin—IKBKB—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—psoriasis	5.71e-05	0.000814	CbGpPWpGaD
Auranofin—IKBKB—Toll-Like Receptors Cascades—JUN—psoriasis	5.7e-05	0.000813	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—TP53—psoriasis	5.69e-05	0.000812	CbGpPWpGaD
Auranofin—Pruritus—Prednisone—psoriasis	5.62e-05	0.000876	CcSEcCtD
Auranofin—IKBKB—Adaptive Immune System—HLA-C—psoriasis	5.61e-05	0.0008	CbGpPWpGaD
Auranofin—IKBKB—BDNF signaling pathway—JUN—psoriasis	5.6e-05	0.000799	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	5.55e-05	0.000792	CbGpPWpGaD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—TNF—psoriasis	5.53e-05	0.000789	CbGpPWpGaD
Auranofin—IKBKB—Toll-Like Receptors Cascades—NFKB1—psoriasis	5.49e-05	0.000783	CbGpPWpGaD
Auranofin—Diarrhoea—Prednisone—psoriasis	5.43e-05	0.000847	CcSEcCtD
Auranofin—Gastrointestinal pain—Methotrexate—psoriasis	5.43e-05	0.000846	CcSEcCtD
Auranofin—Nausea—Betamethasone—psoriasis	5.42e-05	0.000845	CcSEcCtD
Auranofin—Nausea—Dexamethasone—psoriasis	5.42e-05	0.000845	CcSEcCtD
Auranofin—IKBKB—BDNF signaling pathway—NFKB1—psoriasis	5.39e-05	0.000769	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—TP53—psoriasis	5.34e-05	0.000762	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HCAR2—psoriasis	5.33e-05	0.00076	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—NFKB1—psoriasis	5.32e-05	0.000759	CbGpPWpGaD
Auranofin—Urticaria—Methotrexate—psoriasis	5.27e-05	0.000822	CcSEcCtD
Auranofin—Abdominal pain—Methotrexate—psoriasis	5.25e-05	0.000818	CcSEcCtD
Auranofin—IKBKB—Immune System—DDX58—psoriasis	5.22e-05	0.000744	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-DRB1—psoriasis	5.21e-05	0.000744	CbGpPWpGaD
Auranofin—IKBKB—MyD88 cascade initiated on plasma membrane—IL6—psoriasis	5.16e-05	0.000736	CbGpPWpGaD
Auranofin—IKBKB—Insulin Signaling—JUN—psoriasis	5.15e-05	0.000735	CbGpPWpGaD
Auranofin—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	5.11e-05	0.00073	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—TNF—psoriasis	5.09e-05	0.000726	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—IFNG—psoriasis	5.08e-05	0.000725	CbGpPWpGaD
Auranofin—Vomiting—Prednisone—psoriasis	5.05e-05	0.000787	CcSEcCtD
Auranofin—IKBKB—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	5.02e-05	0.000716	CbGpPWpGaD
Auranofin—Rash—Prednisone—psoriasis	5.01e-05	0.000781	CcSEcCtD
Auranofin—IKBKB—Cytokine Signaling in Immune system—ICAM1—psoriasis	5.01e-05	0.000714	CbGpPWpGaD
Auranofin—Dermatitis—Prednisone—psoriasis	5e-05	0.00078	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—JUN—psoriasis	4.95e-05	0.000707	CbGpPWpGaD
Auranofin—IKBKB—TCR Signaling Pathway—IL6—psoriasis	4.93e-05	0.000703	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—NFKBIA—psoriasis	4.88e-05	0.000696	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—HLA-E—psoriasis	4.85e-05	0.000692	CbGpPWpGaD
Auranofin—IKBKB—BDNF signaling pathway—STAT3—psoriasis	4.85e-05	0.000692	CbGpPWpGaD
Auranofin—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	4.85e-05	0.000691	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—IL6—psoriasis	4.85e-05	0.000691	CbGpPWpGaD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	4.79e-05	0.000683	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—NFKB1—psoriasis	4.77e-05	0.00068	CbGpPWpGaD
Auranofin—IKBKB—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	4.76e-05	0.000679	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	4.75e-05	0.000678	CbGpPWpGaD
Auranofin—Nausea—Prednisone—psoriasis	4.72e-05	0.000736	CcSEcCtD
Auranofin—Pruritus—Methotrexate—psoriasis	4.69e-05	0.000732	CcSEcCtD
Auranofin—IKBKB—Adaptive Immune System—HLA-E—psoriasis	4.66e-05	0.000664	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TAGAP—psoriasis	4.62e-05	0.000659	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	4.57e-05	0.000652	CbGpPWpGaD
Auranofin—IKBKB—MyD88-independent cascade—IL6—psoriasis	4.57e-05	0.000652	CbGpPWpGaD
Auranofin—Diarrhoea—Methotrexate—psoriasis	4.54e-05	0.000708	CcSEcCtD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—IL6—psoriasis	4.46e-05	0.000636	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	4.32e-05	0.000616	CbGpPWpGaD
Auranofin—IKBKB—Signaling by Interleukins—IL6—psoriasis	4.26e-05	0.000608	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—NFKB1—psoriasis	4.23e-05	0.000604	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	4.23e-05	0.000603	CbGpPWpGaD
Auranofin—Vomiting—Methotrexate—psoriasis	4.22e-05	0.000658	CcSEcCtD
Auranofin—Rash—Methotrexate—psoriasis	4.18e-05	0.000653	CcSEcCtD
Auranofin—Dermatitis—Methotrexate—psoriasis	4.18e-05	0.000652	CcSEcCtD
Auranofin—ALB—Platelet degranulation—VEGFA—psoriasis	4.14e-05	0.000591	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—TNF—psoriasis	4.14e-05	0.00059	CbGpPWpGaD
Auranofin—IKBKB—Activated TLR4 signalling—IL6—psoriasis	4.11e-05	0.000586	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—IL6—psoriasis	4.11e-05	0.000586	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—TYK2—psoriasis	4.07e-05	0.00058	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—SOCS1—psoriasis	4.05e-05	0.000578	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—TYK2—psoriasis	4e-05	0.00057	CbGpPWpGaD
Auranofin—ALB—Hemostasis—ITGAL—psoriasis	3.98e-05	0.000568	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ITGAL—psoriasis	3.95e-05	0.000564	CbGpPWpGaD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	3.95e-05	0.000563	CbGpPWpGaD
Auranofin—Nausea—Methotrexate—psoriasis	3.94e-05	0.000615	CcSEcCtD
Auranofin—IKBKB—Adaptive Immune System—SOCS1—psoriasis	3.89e-05	0.000555	CbGpPWpGaD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	3.87e-05	0.000552	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IFNG—psoriasis	3.81e-05	0.000543	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—TNF—psoriasis	3.71e-05	0.000529	CbGpPWpGaD
Auranofin—IKBKB—Immune System—REL—psoriasis	3.7e-05	0.000527	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—TP53—psoriasis	3.65e-05	0.000521	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IFIH1—psoriasis	3.59e-05	0.000512	CbGpPWpGaD
Auranofin—ALB—Metabolism—NDUFA5—psoriasis	3.58e-05	0.000511	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	3.48e-05	0.000497	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—HLA-B—psoriasis	3.45e-05	0.000493	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CD8A—psoriasis	3.45e-05	0.000492	CbGpPWpGaD
Auranofin—IKBKB—Toll-Like Receptors Cascades—IL6—psoriasis	3.44e-05	0.000491	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-C—psoriasis	3.4e-05	0.000485	CbGpPWpGaD
Auranofin—IKBKB—Immune System—TNFAIP3—psoriasis	3.36e-05	0.000479	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.34e-05	0.000477	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—IL6—psoriasis	3.34e-05	0.000477	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—CP—psoriasis	3.33e-05	0.000475	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HLA-B—psoriasis	3.32e-05	0.000473	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—TNF—psoriasis	3.29e-05	0.000469	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—TP53—psoriasis	3.27e-05	0.000466	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	3.18e-05	0.000453	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—NFKB1—psoriasis	3.17e-05	0.000452	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—NFKB1—psoriasis	3.12e-05	0.000444	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HLA-A—psoriasis	3.07e-05	0.000438	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CRP—psoriasis	3.05e-05	0.000436	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP2S1—psoriasis	3.05e-05	0.000435	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.87e-05	0.00041	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—STAT3—psoriasis	2.85e-05	0.000406	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-E—psoriasis	2.82e-05	0.000403	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HLA-DRB1—psoriasis	2.81e-05	0.000401	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—STAT3—psoriasis	2.8e-05	0.000399	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—NFKBIA—psoriasis	2.78e-05	0.000397	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CCL20—psoriasis	2.77e-05	0.000395	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—ICAM1—psoriasis	2.7e-05	0.000384	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—NFKBIA—psoriasis	2.67e-05	0.000381	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—IL6—psoriasis	2.65e-05	0.000379	CbGpPWpGaD
Auranofin—IKBKB—Immune System—SOCS1—psoriasis	2.36e-05	0.000336	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—TYK2—psoriasis	2.28e-05	0.000325	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD8A—psoriasis	2.09e-05	0.000298	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CD4—psoriasis	2.06e-05	0.000294	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-B—psoriasis	2.01e-05	0.000287	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL6—psoriasis	1.99e-05	0.000284	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CD4—psoriasis	1.98e-05	0.000283	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—IL6—psoriasis	1.96e-05	0.000279	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-A—psoriasis	1.86e-05	0.000266	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—JUN—psoriasis	1.85e-05	0.000263	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.84e-05	0.000262	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CRP—psoriasis	1.78e-05	0.000254	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—NFKB1—psoriasis	1.78e-05	0.000253	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—NFKB1—psoriasis	1.71e-05	0.000243	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-DRB1—psoriasis	1.7e-05	0.000243	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ICAM1—psoriasis	1.63e-05	0.000233	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS2—psoriasis	1.63e-05	0.000233	CbGpPWpGaD
Auranofin—IKBKB—Immune System—NFKBIA—psoriasis	1.62e-05	0.000231	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.6e-05	0.000228	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SOCS1—psoriasis	1.52e-05	0.000218	CbGpPWpGaD
Auranofin—ALB—Metabolism—CARM1—psoriasis	1.49e-05	0.000212	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.39e-05	0.000198	CbGpPWpGaD
Auranofin—IKBKB—Immune System—TYK2—psoriasis	1.33e-05	0.000189	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IFNG—psoriasis	1.24e-05	0.000177	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD4—psoriasis	1.2e-05	0.000171	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—LEP—psoriasis	1.13e-05	0.000161	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—APOE—psoriasis	1.13e-05	0.000161	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—IL6—psoriasis	1.12e-05	0.000159	CbGpPWpGaD
Auranofin—IKBKB—Immune System—JUN—psoriasis	1.08e-05	0.000153	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NFKBIA—psoriasis	1.05e-05	0.00015	CbGpPWpGaD
Auranofin—IKBKB—Immune System—NFKB1—psoriasis	1.04e-05	0.000148	CbGpPWpGaD
Auranofin—ALB—Hemostasis—VEGFA—psoriasis	9.47e-06	0.000135	CbGpPWpGaD
Auranofin—IKBKB—Immune System—STAT3—psoriasis	9.3e-06	0.000133	CbGpPWpGaD
Auranofin—ALB—Metabolism—CAT—psoriasis	9.15e-06	0.000131	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TYK2—psoriasis	8.59e-06	0.000123	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CXCL8—psoriasis	7.48e-06	0.000107	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TP53—psoriasis	7.15e-06	0.000102	CbGpPWpGaD
Auranofin—ALB—Metabolism—APOE—psoriasis	7.11e-06	0.000101	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—JUN—psoriasis	6.95e-06	9.92e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NFKB1—psoriasis	6.69e-06	9.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL6—psoriasis	6.5e-06	9.27e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PPARG—psoriasis	6.2e-06	8.84e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—VEGFA—psoriasis	6.07e-06	8.66e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—STAT3—psoriasis	6.01e-06	8.58e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TP53—psoriasis	4.59e-06	6.55e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IL6—psoriasis	4.2e-06	5.99e-05	CbGpPWpGaD
